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Multiple myeloma–associated chromosomal 
translocation activates orphan snoRNA  
ACA11 to suppress oxidative stress
Liang Chu,1 Mack Y. Su,1 Leonard B. Maggi Jr.,1 Lan Lu,1 Chelsea Mullins,1  
Seth Crosby,2 Gaofeng Huang,3 Wee Joo Chng,3,4,5,6 Ravi Vij,1 and Michael H. Tomasson1,2
1Division of Oncology and 2Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA.  
3Yong Loo Lin School of Medicine, 4Department of Haematology-Oncology, National University Cancer Institute of Singapore,  
5National University Health System, and 6Cancer Science Institute of Singapore, National University of Singapore, Singapore.
The histone methyltransferase WHSC1 (also known as MMSET) is overexpressed in multiple myeloma (MM) 
as a result of the t(4;14) chromosomal translocation and in a broad variety of other cancers by unclear mecha-
nisms. Overexpression of WHSC1 did not transform wild-type or tumor-prone primary hematopoietic cells. 
We found that ACA11, an orphan box H/ACA class small nucleolar RNA (snoRNA) encoded within an intron 
of WHSC1, was highly expressed in t(4;14)-positive MM and other cancers. ACA11 localized to nucleoli and 
bound what we believe to be a novel small nuclear ribonucleoprotein (snRNP) complex composed of sev-
eral proteins involved in postsplicing intron complexes. RNA targets of this uncharacterized snRNP included 
snoRNA intermediates hosted within ribosomal protein (RP) genes, and an RP gene signature was strongly 
associated with t(4;14) in patients with MM. Expression of ACA11 was sufficient to downregulate RP genes 
and other snoRNAs implicated in the control of oxidative stress. ACA11 suppressed oxidative stress, afforded 
resistance to chemotherapy, and increased the proliferation of MM cells, demonstrating that ACA11 is a criti-
cal target of the t(4;14) translocation in MM and suggesting an oncogenic role in other cancers as well.
Introduction
Multiple myeloma (MM) is an incurable cancer of B-lineage plasma 
cells, associated with anemia, renal failure, and cortical bone destruc-
tion (1). The recurrent t(4;14)(p16.3;q32.3) chromosomal transloca-
tion is detected in 20% of MMs and is associated with shortened 
overall survival (2–5). The t(4;14) transposes immunoglobulin heavy 
chain region enhancer elements to the 5′ end of the Wolf-Hirschhorn 
syndrome candidate 1 gene (WHSC1; also known as MMSET and 
NSD2) to drive its ectopic expression (4, 6). WHSC1 encodes 3 
protein isoforms that are expressed as a result of alternative splic-
ing (WHSC1-I and WHSC1-II) and an internal promoter (REIIBP; 
refs. 6, 7, and Supplemental Figure 1A; supplemental material available 
online with this article; doi:10.1172/JCI63051DS1). The WHSC1-II 
and REIIBP isoforms contain a SET domain that encodes a histone 
methyltransferase (HMT), with activity reported toward H4K20 (8, 9), 
H3K36 (10, 11), and H3K27 (12). The HMT activity of WHSC1-II 
plays a role in DNA damage responses by recruiting repair factors to 
DNA breaks, and this recruitment is dependent upon phosphoryla-
tion of WHSC1-II Ser102 by ATM (9, 13).
Three lines of evidence support the role of WHSC1 as an onco-
gene. First, WHSC1 transcripts are consistently overexpressed in 
t(4;14)-positive myelomas, and WHSC1 is also upregulated by 
unknown mechanisms in subsets of diverse solid tumor types, 
including neuroblastoma, in which high WHSC1 levels are associ-
ated with tumor aggressiveness (14–16). Second, transcriptional 
deregulation by the HMT encoded by WHSC1 is a plausible mech-
anism of carcinogenesis. Indeed, H3K36 methyltransferase activity 
can be sufficient to initiate malignant transformation (17), and 
attractive candidate target genes and pathways have been identi-
fied for WHSC1 (18, 19). Third, WHSC1 knockdown using shRNAs 
decreases cell growth and cell adhesion in MM and neuroblasto-
ma cell lines (8, 10, 15, 20). Knockdown using a variety of shRNA 
constructs has established the dependence of transformed cells on 
WHSC1 expression, but which WHSC1 isoform is responsible for 
cell transformation has not been clearly established.
A difficult-to-explain clue into the cell biology of WHSC1 is 
that a subset of t(4;14) patients with MM harbor translocation 
breakpoints that result in the overexpression of amino-truncated 
WHSC1 proteins. Loss of a nucleolar exclusion signal at the amino 
terminus of WHSC1-II causes altered subcellular localization of 
these shortened WHSC1 protein products (21), and Ser102 is lost in 
these truncations, affecting function of WHSC1 in DNA repair (9). 
Yet, the clinical course of t(4;14)-positive patients is independent of 
the location of the translocation breakpoints within WHSC1 (21). 
Therefore, the precise mechanism by which these different WHSC1 
gene products contribute to transformation remains unclear.
To improve our understanding of how the t(4;14) contributes to 
myelomagenesis, we evaluated the effects of 3 major WHSC1 isoforms 
(WHSC1-I, WHSC1-II, and REIIBP) on hematopoietic cell trans-
formation. Despite an extensive set of reverse genetic experiments, 
none of the WHSC1 proteins demonstrated significant pro-growth 
effects. These unexpected results prompted us to examine the 4p16.3 
breakpoint region in t(4;14)-positive patients with MM for a missing 
oncogene. Using RNA tiling arrays, we identified what we believe to 
be a novel box H/ACA ncRNA, ACA11, encoded within intron 18–19 
of the WHSC1 gene overexpressed in t(4;14)-positive MM and other 
cancers. ACA11 is an orphan small nucleolar RNA (snoRNA) that 
binds what we believe to be a novel small nuclear ribonucleoprotein 
(snRNP) complex in MM cells. Overexpression of ACA11 protected 
MM cells from oxidative stress and modulated tumor proliferation, 
and knockdown of ACA11 slowed cell proliferation and sensitized 
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MM cells to cytotoxic chemotherapy. The discovery of a snoRNA 
within WHSC1, a “missing ingredient” overexpressed as a result of the 
t(4;14), provides an important molecular target in MM pathogenesis.
Results
WHSC1 cDNAs are not sufficient to induce malignant transformation. Onco-
genic activity has been reported for WHSC1 (10, 18, 19), so we sought 
to compare the transformation potential of the 3 major WHSC1 
isoforms. However, overexpression of WHSC1-I, WHSC1-II, and 
REIIBP did not affect NIH/3T3 fibroblast cell proliferation and did 
not protect cells from cytotoxic chemotherapy or protect hematopoi-
etic Ba/F3 cells from growth factor withdrawal (Supplemental Fig-
ure 1 and data not shown). To assess the effects of WHSC1 isoforms 
overexpressed in animals, we developed transgenic strains of mice 
expressing WHSC1-I, WHSC1-II, or REIIBP cDNAs under the control 
of the B cell–specific immunoglobulin heavy chain enhancer and pro-
moter (Eμ). None of the Eμ-WHSC1 mice had any significant hemato-
poietic phenotype after 2 years (data not shown). Next, we expressed 
WHSC1 isoform transcripts more broadly in primary murine hema-
topoietic cells using ecotropic retroviruses encoding WHSC1-I, 
WHSC1-II, or REIIBP introduced into bone marrow mononuclear 
cells transplanted into lethally irradiated syngeneic recipients (BMT 
recipients). WHSC1 BMT recipients had no detectable hematopoietic 
phenotype after 1 year of observation using wild-type or tumor-prone 
Cdkn2a–/– (Arf/Ink4a-null) (22) mice as bone marrow donors (Supple-
mental Figure 2 and data not shown). While these negative results 
do not exclude the possibility that WHSC1 proteins contribute to 
myelomagenesis, they prompted us to reexamine the t(4;14) break-
point locus at 4p16.3 for an additional oncogenic element.
A noncoding RNA within WHSC1 is overexpressed in t(4;14)-positive 
MM and other cancers. To identify additional oncogenes on chromo-
some 4 in an unbiased fashion, we designed oligonucleotide tiling 
arrays spanning the t(4;14) breakpoint region on chromosome 4 
(Figure 1A). In samples from patients with MM, expressed RNAs 
most significantly associated with t(4;14) status mapped to the 
WHSC1 locus (P = 6.33 × 10–5; Table 1). Notably, in addition to 
WHSC1 exon sequences, 1 substantial segment mapped to ACA11 
(SCARNA22), a 125-bp noncoding RNA (ncRNA) located within 
intron 18–19 of WHSC1 (Figure 1, B and C, and Supplemental 
Figure 3, A and B). Robust expression of ACA11 was significant-
ly associated with the t(4;14) translocation in MM cell lines and 
patient samples (Figure 1, D–F). ACA11 was also overexpressed in 
a subset of samples from patients with primary colon, esophageal, 
and bladder cancer (Figure 2), consistent with its location within 
WHSC1 (16). These data confirm ACA11 overexpression in t(4;14)-
positive MM, but additional studies are required to confirm the 
hypothesis that ACA11 is upregulated in other cancer types.
ACA11 is a box H/ACA snoRNA. The predicted secondary structure 
of ACA11 was typical of box H/ACA ncRNAs and revealed 2 hair-
pin elements connected by a single-stranded hinge carrying the 
canonical H box (AnAnnA) followed by a 3′ tail containing the ACA 
box (Figure 3A). ACA11 is evolutionarily conserved (Supplemen-
tal Figure 3C), but the murine homolog of ACA11 (SCARNA23), 
with 82% sequence homology to ACA11, is hosted by a different, 
distant gene in mice (Supplemental Figure 3D), consistent with 
the categorization of box H/ACA snoRNAs as retroposon-associ-
ated mobile genetic elements (23).
Box H/ACA RNAs can accumulate either in nucleoli (i.e., snoRNAs) 
or in the nucleoplasmic Cajal bodies (i.e., small Cajal body–specif-
ic RNAs [scaRNAs]) (24), and we sought to better classify ACA11 
based on its subcellular localization. Using in situ hybridization 
followed by immunofluorescence in t(4;14)-positive H929 MM 
cells, we found that ACA11 localized to dot-like nuclear struc-
tures. Costaining the same cells with a marker of Cajal bodies 
demonstrated that the majority of ACA11 RNA did not localize to 
Cajal bodies (Figure 3B). On the other hand, we found that ACA11 
colocalized with GFP-tagged nucleophosmin (NPM1), a marker of 
nucleoli (Figure 3C and ref. 25). To confirm the nucleolar localiza-
tion of ACA11, stably transfected Arf–/– mouse embryonic fibro-
blasts (MEFs) were separated into cytoplasmic, nucleoplasmic, and 
nucleolar fractions and subjected to Northern blot analysis for 
ACA11. ACA11 was predominantly localized to the nucleolar frac-
tion and was not detectable in either cytoplasmic or nucleoplasmic 
fractions (Figure 3D). Although these data do not exclude a role 
for small amounts of ACA11 in Cajal bodies, based on its predomi-
nant nucleolar localization, we classified ACA11 as a snoRNA.
ACA11 binds nucleolar proteins implicated in RNA processing. Box 
H/ACA snoRNAs function as guide RNAs for snRNP complexes 
(26). To test whether ACA11 physically associates with nuclear pro-
teins, we performed RNA EMSA. The migration of labeled ACA11 
RNA was slowed after incubating with H929 cell nuclear extracts, 
demonstrating a physical interaction of ACA11 with nuclear pro-
teins (Figure 4A). We then used RNA affinity purification followed 
by mass spectrometry (MS) to identify specific protein partners of 
ACA11 in t(4;14)-positive MM cells (Figure 4B and Table 2). Using 
molecular pathway analysis, most identified proteins that bound to 
ACA11 (Supplemental Table 1) were implicated in RNA processing 
(Supplemental Table 2), including RNA splicing factors (SF3B1, 
SF3B2, and SFPQ), ATP-dependent RNA helicase A (DHX9), RNA-
specific adenosine deaminase (ADAR), and 8 members of the het-
erogeneous nuclear ribonucleoprotein family (HNRNP). Western 
blot of RNA affinity-purified lysates confirmed that 9 proteins 
identified by MS specifically bound to ACA11 (Figure 4C). Nota-
bly, dyskerin and other well-characterized components of the pseu-
douridylation machinery that comprise other box H/ACA snoRNA 
snRNPs (27) were absent from the ACA11 snRNP.
Figure 1
ACA11 is activated by t(4;14) in MM. (A) Schematic diagram of the 
chromosome 4p16.3 tiling oligonucleotide microarray, spanning 430 Kb 
across the t(4;14) breakpoint region (breakpoints are indicated by 
arrows). Annotated genes are indicated with exon structures. (B) Til-
ing microarray expression data of representative t(4;14)-positive and 
-negative patients with MM. (C) Heat map of t(4;14)-positive (Y; n = 4) 
and -negative (N; n = 12) patient samples. (B and C) Numbers indicate 
base pairs on chromosome 4 (human genome assembly GRCh37). 
(D) Real-time PCR of ACA11 in samples from patients with MM. The 
inset shows that ACA11 is significantly associated with t(4;14) status. 
Normal, normal plasma cells (n = 10); t(4;14)+, t(4;14)-positive patient 
samples (n = 6); t(4;14)–, t(4;14)-negative patient samples (n = 57). (E) 
Northern blot of ACA11 expression in human MM cell lines. t(4;14)-pos-
itive cell lines included KMS-11, OPM-2, LP-1, and H929 cells; t(4;14)-
negative cell lines included U266, RPMI8226, and MM.1S cells; and 
non-MM cell lines included K562, HeLa, A375, and U1A cells. Loading 
controls were 28S and 18S rRNA. (F) ACA11 expression by real-time 
PCR is significantly associated with t(4;14) in MM cell lines. qRT-PCR 
data in D and F were normalized to the mean of 3 reference genes 
(GAPDH, UBC, YWHAZ). Data are presented as mean ± SD, with a 
box-whisker plot of minimum-to-maximum values (inset) (n = 3). The 
line within the box is the median value. The box represents the first 
and third quartiles. The whiskers show the largest and smallest events 
within at least 1.5 times the size of the box from the nearest edge.
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To confirm association between these proteins and ACA11, we 
performed cross-linking immunoprecipitation (CLIP) followed 
by RT-PCR. ACA11 RNA was readily detectable in both DHX9 
and IL enhancer-binding factor 3 (ILF3) immunoprecipitates in 
H929 cells (Figure 4D). We also used immunoprecipitation–West-
ern analysis to evaluate protein-protein interactions within the 
ACA11 complex. Endogenous ILF3 was readily identified in DHX9 
immunoprecipitates, as were the candidate ACA11-binding pro-
teins nucleolin (NCL), ADAR, and HNRNPU (Figure 4E). These 
results were confirmed in a second t(4;14)-positive MM cell line 
(LP-1; data not shown). DNA-dependent protein kinase catalytic 
subunit (DNA-PK) and SF3B1 immunoreactive bands were less 
intense, suggesting weaker or indirect binding to DHX9 (data not 
shown). In MM cells, therefore, ACA11 appeared to participate in 
a unique snRNP complex composed of at least DHX9, ILF3, NCL, 
ADAR, and HNRNPU. Additional studies are required to confirm 
the components of this snRNP in live cells.
RNA targets of the ACA11 snRNP include a set of snoRNA intermediates. 
To identify RNA substrates of the ACA11 snRNP, we immuno-
precipitated ILF3 from H929 cells and subjected isolated RNA to 
deep sequencing (Supplemental Figure 4). Among the 50 most 
abundant sequences (Supplemental Table 3), the largest number 
of sequence reads (626,876) mapped to snoRNA genes (Table 3). 
Six of these snoRNAs are positioned within ribosomal protein 
(RP) gene hosts. More precisely, these reads uniformly mapped 
sharply to the 5′ ends of snoRNA genes, spanned the snoRNAs, 
and extended into 3′ intronic and exonic regions of the host RP 
genes (Figure 5, A–G). Sequence data were confirmed by RT-PCR 
of snoRNA genes in ILF3 and SF3B1 immunoprecipitates in 2 MM 
cell lines (Figure 5H). These results suggest that ACA11 snRNP 
complexes interact with a set of snoRNA intermediates character-
ized by sequences partially excised from their host introns at their 
5′ end but retaining a 3′ intronic tail.
ACA11 downregulates RP genes without affecting ribosomal biogenesis or 
cell growth. At the same time, we sought to identify an mRNA expres-
sion signature associated with t(4;14)-positive MM using available 
microarray data from 239 patients with MM. We compared the 
WHSC1 expression cluster [i.e., t(4;14)] pairwise with 5 other defined 
MM expression clusters to identify a prioritized list of gene expres-
sion changes specifically associated with t(4;14)-positive myeloma 
cases. As expected, the WHSC1 and FGFR3 genes closest to chromo-
some 4 breakpoints were highly expressed in t(4;14)-positive cases 
(Figure 6). Among the total 260 probes, we found 192 probes (111 
unique genes) upregulated and 68 probes (50 unique genes) downreg-
ulated in t(4;14)-positive cases (Supplemental Table 4). We analyzed 
the t(4;14) signature genes using the Kyoto Encyclopedia of Genes 
and Genomes database. Strikingly, there was a powerful association 
between t(4;14) and downregulation of RP genes (P = 4.8 × 10–20; 
Supplemental Table 5) in samples from patients with MM.
snoRNAs function primarily as guide RNAs for the pseudouri-
dylation of ribosomal and spliceosomal RNAs, but additional 
roles for this large class of ncRNAs likely remain undiscovered. We 
sought to explore the possible role of ACA11 in cancer and began 
by determining whether ACA11 expression mediated the downreg-
ulation of RP gene transcripts that we observed in t(4;14)-positive 
patients with MM. Consistent with the mRNA expression signature 
observed (Figure 6), we found that ACA11 expression significantly 
suppressed certain RP gene transcripts and steady-state ribosome 
protein levels in MEFs (Figure 7, A–D) and in MM cells (Figure 7, 
E–H). Intriguingly, however, overexpression of ACA11 did not sig-
nificantly affect ribosomal subunit assembly (data not shown) or 
polysome formation (Supplemental Figure 5A), and ACA11 over-
expression did not affect cell volume or cell mass, hallmarks of 
ribosomal biogenesis (Supplemental Figure 5, B and C). Recently, 
box C/D snoRNAs resident in the RP gene RPL13A were found to 
mediate cell death in response to oxidative stress (28). Importantly, 
we noted that RPL13A and snoRNA U33 at that locus were down-
regulated by ACA11 in MM cells (Figure 7, G–I). These findings 
lead us to test the effect of ACA11 expression on oxidative stress.
ACA11 modulates oxidative stress responses and contributes to MM cell 
proliferation. ACA11 overexpression significantly lowered basal 
levels of ROS and suppressed ROS levels following challenge 
with hydrogen peroxide (H2O2) in MEFs (Figure 8A). To evalu-
ate its effect in human MM cells, we overexpressed ACA11 in the 
t(4;14)-negative MM.1S cell line, and these cells had significantly 
reduced ROS levels at baseline and in response to challenge with 
peroxide (Figure 8B). Furthermore, overexpression of ACA11 
increased proliferation (Figure 8, C and D) and conferred resis-
tance to cytotoxic chemotherapy in t(4;14)-negative MM.1S cells 
(Figure 8E). Next, we knocked down ACA11 in t(4;14)-positive 
H929 human MM cells using antisense oligonucleotides (ASOs; 
Figure 3A, Figure 8, F and G, and Supplemental Figure 6, A–D). 
Table 1
List of tiling array probe segments associated with t(4;14) status in samples from patients with MM
Chr. Start Stop Gene ID Region Mean amp. No. Length (bp)
4p16.3 1920143 1929297 WHSC1 Exon 6 4,141 8 155
4p16.3 1940066 1940409 WHSC1 Exon 9 3,071 8 344
4p16.3 1976595 1976694 WHSC1 Exon 20 3,057 9 100
4p16.3 1950163 1950295 WHSC1 UTR 3,040 8 133
4p16.3 1946890 1947026 WHSC1 UTR 2,791 7 137
4p16.3 1976346 1976570 ACA11 Intron 18–19 2,494 7 225
4p16.3 1918558 1919898 WHSC1 Exon 5 2,462 16 1341
4p16.3 1920919 1921041 WHSC1 Intron 6-7 2,420 11 123
4p16.3 1920297 1920919 WHSC1 UTR 2,273 17 623
4p16.3 1961171 1961639 WHSC1 Exon 18 1,971 21 469
Top 10 probe regions most significantly associated with t(4;14) (P = 6.33 × 10–5, χ2 = 16). Start and stop are the beginning and end of the segment (in chro-
mosome 4 base pairs) significantly associated with t(4;14). The segment of interest is indicated in bold. Chr., chromosome cytoband; Mean amp., average 
probe amplification in arbitrary units; No., number of probes in segment; Length, length of amplified segment.
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ACA11 knockdown significantly increased ROS production (Fig-
ure 8H), decreased cell proliferation as measured by cell counts 
and BrdU incorporation (Figure 8, I and J), and sensitized MM 
cells to chemotherapy (Figure 8K). Knockdown of ACA11 also 
significantly reduced growth of MM tumors in mice (Figure 8, 
L–O). Importantly, knockdown of ACA11 did not alter WHSC1-I, 
WHSC1-II, or REIIBP protein levels (Supplemental Figure 6E), 
but knockout of WHSC1 by other investigators (20) resulted in 
loss of ACA11 expression (Supplemental Figure 6F). Knockdown 
of ACA11 to undetectable levels in ACA11-low RPMI8226 MM 
cells also increased ROS levels, decreased cell proliferation, and 
reduced growth of tumors in mice, suggesting that ACA11 func-
tions even at low levels in t(4;14)-negative MM cells (Figure 8, N 
and O, and Supplemental Figure 7). These results demonstrate 
that ACA11 suppresses oxidative stress, facilitates cell prolifera-
tion, and protects cells from the effects of chemotherapy.
Discussion
WHSC1 proteins are consistently expressed as a consequence of the 
t(4;14) and are required for the survival of MM cell lines. Surpris-
ingly, we found no phenotype for WHSC1 cDNA isoforms in a range 
of overexpression assays. WHSC1 overexpression had no effect on 
Figure 2
ACA11 is overexpressed in bladder, colon, and esophageal cancers. (A–C) ACA11 is overexpressed in samples from patients with (A) bladder, 
(B) colon, and (C) esophageal cancer. Heat maps of RNA expression at the ACA11 locus were measured using our custom chromosome 4 tiling 
arrays. Each bar represents the normalized mean expression value obtained from quadruplicate probes representing each physical location. 
Numbers indicate base pairs on chromosome 4 (human genome assembly GRCh37). (D–F) Graphs of data shown in A–C. ACA11 levels in (D) 
bladder, (E) colon, and (F) esophagus samples were plotted using raw expression values of 4 probes. Intron, intron 18–19 of WHSC1 upstream 
of ACA11. Data in D–F are presented as mean ± SD (n = 4). M, malignant tumor samples. N, normal control samples.
Downloaded on October 17, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/63051
research article
2798 The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 8   August 2012
Figure 3
ACA11 localizes to nucleoli. (A) Predicted secondary structure of ACA11. Red 
brackets indicate H box, ACA box, and CAB motifs. Black lines indicate ASOs. 
(B) Endogenous ACA11 is not significantly localized to Cajal bodies (coilin, 
red) in MM cells. ACA11 or β-actin is in green; DNA (DAPI) is in blue. Scale bar: 
5 μm. (C) Localization of ACA11 to nucleoli. ACA11 or β-actin is shown in red; 
NPM1 is shown in green; DNA (DAPI) is in blue. Scale bar: 5 μm. (D) Northern 
blot (top 2 panels) for ACA11 in cytoplasmic (CP), nucleoplasmic (NP), and 
nucleolar (NS) fractions. Western blot (bottom 3 panels) of cytoplasmic (SOD), 
nuclear (NUP62), and nucleolar (NPM1) markers.
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proliferation either in lymphoid Ba/F3 or immortalized NIH/3T3 
cells (Supplemental Figure 1). Similarly, we found no phenotype in 
Eμ-WHSC1-I, WHSC1-II, or REIIBP transgenic mice or in wild-type 
murine bone marrow transduction-transplantation (BMT) experi-
ments. Unpublished studies suggest that WHSC1 overexpression 
in primary B cells may have cell death-promoting effects (P. Leif 
Bergsagel, unpublished observations), and the potential toxicity of 
WHSC1 was the rationale for our use of Cdkn2a knockout (null for 
both Ink4a and Arf) mice as bone marrow donors in follow-up BMT 
experiments. Using tumor-prone, apoptosis-resistant Cdkn2a–/– 
mice as bone marrow donors, we overexpressed WHSC1 isoforms in 
primary hematopoietic cells (Supplemental Figure 2D). However, 
even in this permissive genetic background, none of the WHSC1 
isoforms perturbed normal hematopoiesis (Supplemental Figure 
2). Negative results do not exclude an important role for WHSC1 
proteins in MM cell transformation, but they stimulated our search 
for a missing ingredient in t(4;14) biology. We analyzed transcripts 
deregulated by the t(4;14) at the 4p16.3 locus in an unbiased fashion 
using expression tiling arrays and uncovered what we believe to be 
a new piece to the puzzle: a snoRNA embedded within the WHSC1 
locus. ACA11 is a small (125-bp) nucleolar-localized RNA (i.e., 
snoRNA), with a double-hairpin structure and box H and box ACA 
domains (Figure 3A). Box H/ACA snoRNAs play roles in splicing 
and ribosome biogenesis by guiding the pseudouridylation of spli-
ceosomal and ribosomal RNAs, but ACA11 is an orphan snoRNA 
with no known RNA target.
Using custom tiling arrays, we detected the expression of ACA11 
in MM and other cancers in a pattern consistent with the physical 
linkage of this snoRNA to WHSC1 (Figure 1, B and C, and Figure 2). 
We confirmed ACA11 expression in MM cell lines using Northern 
blots (Figure 1E). We also developed a quantitative real-time PCR 
(qRT-PCR) assay for ACA11 using 3 housekeeping gene controls 
to accurately measure ACA11 levels in 11 cell lines and 63 samples 
from patients with MM (Figure 1, D and F). ACA11 was significantly 
associated with t(4;14) in MM cell lines (P = 0.0167) and in patients 
with MM (P < 0.0001). Despite this strong association, ACA11 
was overexpressed in some t(4;14)-negative cell lines and patient 
samples, which we did not find surprising. Up to 25% of t(4;14)-
negative cases upregulate WHSC1 transcripts to the same level as 
that in t(4;14)-positive cases (14, 29), suggesting that WHSC1 is 
deregulated by mechanisms besides t(4;14). Furthermore, WHSC1 
is overexpressed in neuroblastoma, colon, esophageal, and bladder 
cancers that do not harbor the t(4;14) (14–16). ACA11 overexpres-
sion in primary bladder, colon, and esophageal cancer samples sug-
Figure 4
ACA11 binds a noncanonical ribonucleoprotein complex consisting of a set of proteins implicated in RNA processing. (A) RNA EMSA confirming 
ACA11 binding to proteins from H929 cell nuclear extracts. Competitor, unlabeled ACA11 RNA. (B) Coomassie-stained SDS-PAGE gel of ACA11 
pull-downs used for identification of proteins binding to ACA11 by MS. Representative proteins with the most abundant, unique peptides in each 
indicated band are marked with numbers that correspond to those in Table 2. M, protein marker. (C) Confirmation of ACA11-binding proteins by 
Western blot. The ACA11-protein complex was purified as in B and subjected to Western blot with antibodies to proteins identified by MS. The 
asterisk indicates nonspecific binding. Hsp90 was used as a negative control. (D) Confirmation of ACA11 presence in a DHX9/ILF3 ribonucleo-
protein complex by CLIP followed by RT-PCR using H929 cells. H2O was used as a water template for RT-PCR. GAPDH was used as an internal 
control. M, DNA marker. (E) Physical interaction of ACA11 ribonucleoprotein complex proteins NCL, ILF3, ADAR, and HNRNPU with DHX9 in 
H929 cells was confirmed by immunoprecipitation.
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gests a potential role for ACA11 in nonhematopoietic tumors (Fig-
ure 2). Activation of ACA11 by more than one mechanism may be 
considered a sign of its importance to tumor biology.
We confirmed by confocal microscopy and cell fractionation 
studies that ACA11 localized predominantly to cell nucleoli in 
MEF cells overexpressing ACA11 (Figure 3D). snoRNAs are nucle-
olar-localized ncRNAs, which serve as template guides for the 
posttranscriptional modification of target ribosomal and spliceo-
somal RNAs (24). We can not exclude the possibility that during 
normal development endogenous ACA11 might localize to Cajal 
bodies (i.e., and be categorized as a scaRNA), but in this setting our 
data categorize ACA11 as a snoRNA. After the telomerase RNA 
subunit, ACA11 is the only the second box H/ACA class snoRNA 
to our knowledge with a role in cancer and the first to be directly 
activated in cancer by chromosomal translocation.
We found ACA11 to be a component of a novel snRNP complex. 
Box H/ACA snoRNAs function primarily as guide RNAs for the dys-
kerin snRNP complex responsible for pseudouridylation of ribo-
somal RNAs (27). MS analysis of ACA11-binding proteins revealed 
a cohort of proteins distinct from the canonical box H/ACA 
snoRNA-binding proteins: SF3B1, RNA helicase A, ADAR, and sev-
eral members of the heterogeneous nuclear ribonucleoprotein fam-
ily (HNRNPR, HNRNPL, HNRNPM, HNRNPK, and HNRNPU; 
Figure 4B and Table 2). We confirmed ACA11 interaction with 5 
highly expressed proteins by Western blotting of ACA11 snoRNA 
pull-downs (Figure 4, C–E). We did not find any protein com-
ponents of the dyskerin snRNP binding to ACA11 in MM cells. 
Instead, the ACA11 snRNP appears to be a novel complex involved 
in regulation of RNA processing. Deep sequencing experiments 
revealed an unusual species of RNA, consisting of partially pro-
cessed snoRNAs (Figure 5 and Table 3). We propose that the ACA11 
snRNP is required for the 3′ processing of select snoRNAs. Addi-
tional work will be required to characterize the biochemistry of this 
snRNP and the targets that may be relevant to cancer biology.
Gene targeting at the human WHSC1 locus must be performed 
with caution, because ACA11 expression is coupled to that of 
WHSC1. ACA11 knockdown by ASOs did not affect WHSC1 pro-
tein levels, but ACA11 expression was drastically reduced in KMS-11 
MM cells with WHSC1 knocked out by homologous recombination 
(TKO1 and TKO2 cells; Supplemental Figure 6, E and F). Kuo et al. 
(18) recently used KMS-11 and TKO2 cells as a foundation to iden-
tify target genes of WHSC1 and proposed that WHSC1 HMT activ-
ity activates an oncogenic program. These authors first compared 
gene expression profiles of KMS-11 cells (WHSC1 intact) and TKO2 
cells (WHSC1 deleted) as an initial screen for WHSC1 target genes, 
but TKO2 cells are in fact knocked out for ACA11 as well, not just 
WHSC1. These authors used WHSC1 cDNA constructs (i.e., without 
ACA11) to demonstrate the specificity of HMT regulation of specific 
oncogenes (e.g., TGFA and MET), but it remains unclear which HMT-
induced genes contribute to t(4;14)-positive MM disease behavior. 
Kuo also demonstrated that WHSC1 cDNAs transformed primary 
Arf-null fibroblasts (MEFs), which we cannot reconcile with our data 
except to say that we used different assays for transformation (BMT 
compared with methylcellulose). WHSC1 expression certainly plays 
an important role in t(4;14)-mediated transformation. We propose 
that WHSC1 and ACA11 are 2 distinct cancer genes encoded at the 
same locus, much as Arf and Ink4a are both encoded by the Cdkn2a 
locus. Future studies of WHSC1 effects in tumor biology should 
take into account the fact that ACA11 is a distinct entity within the 
WHSC1 locus that can significantly affect cell behavior.
We found that a major component of the t(4;14) mRNA expres-
sion profile in samples from patients with MM, i.e., downregula-
tion of RP genes (Figure 6), can be attributed to ACA11 expression. 
Downregulation of RP genes has been observed in patients with 
MM by other investigators but without explanation (30). Genes 
involved in protein biosynthesis, including RP genes, are relatively 
upregulated in hyperdiploid MM due to chromosomal copy num-
ber abnormalities (31), but the RP gene signature that we observed 
is unlikely due simply to nonhyperdiploidy, because we used 
recursive analysis to identify a gene signature specifically associ-
ated with t(4;14). We demonstrated that ACA11 was sufficient to 
downregulate a handful of t(4;14)-associated RP genes (Figure 7).
We assessed the downstream effects of ACA11 on ribosome func-
tion by testing polysome formation, cell growth, and cell volume 
but found no significant changes upon overexpression of ACA11 
Table 2
Representative proteins with most unique peptides
No. Proteins names and abbreviations
1 DNA-dependent protein kinase catalytic subunit (DNA-PK)
2 Myb-binding protein 1A (MYBBP1A)
3 Splicing factor 3B subunit 1 (SF3B1)
4 ATP-dependent RNA helicase A (DHX9)
5 SWI/SNF-related matrix-associated actin-dependent regulator  
 of chromatin subfamily A member 5 (SMARCA5)
6 RNA-specific adenosine deaminase (ADAR)
 Heterogeneous nuclear ribonucleoprotein U (HNRNPU)
7 IL enhancer-binding factor 3 (ILF3)
 Nucleolin (NCL)
 Pre-mRNA-processing factor 6 (PRPF6)
8 Nucleolar RNA helicase 2 (DDX21)
9 Far upstream element-binding protein 2 (KHSRP)
10 Heterogeneous nuclear ribonucleoprotein R (HNRNPR)
11 Heterogeneous nuclear ribonucleoprotein M (HNRNPM)
12 Guanine nucleotide-binding protein-like 3 (GNL3)
13 Prelamin-A/C (LMNA)
14 Heterogeneous nuclear ribonucleoprotein L (HNRNPL)
 Heterogeneous nuclear ribonucleoprotein K (HNRNPK)
15 Polypyrimidine tract-binding protein 1 (PTBP1)
16 Heterogeneous nuclear ribonucleoprotein H (HNRNPH1)
17 IL enhancer-binding factor 2 (ILF2)
18 Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)
Numbers correspond with those in Figure 4B.
Table 3
Summary of deep sequencing data
Category Genes Total tags
snoRNAsA 22 626,876
RNP components 7 110,071
Pseudogenes 4 226,355
Histone genes 3 16,319
Other 14 444,610
The top 50 RNAs bound to ILF3 listed by total number of sequencing 
tags and divided into major categories. The largest number of reads 
mapped to snoRNA loci. RNP components include spliceosomal non-
coding snRNP RNAs, including U5 and U3. Total tags, the total number 
of sequencing reads mapped back to each peak. ASix snoRNAs in this 
category mapped to RP host genes.
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(Supplemental Figure 5). Rather, as revealed by deep sequencing 
of ACA11 snRNP RNAs, the molecular targets of ACA11 appear 
to be snoRNAs, hosted within RP genes. Recently, RPL13A and its 
resident snoRNAs were found to mediate ROS (28), and we found 
that ACA11 expression protected cells from oxidative stress and 
cytotoxic chemotherapy. We used 3 MM cell lines for functional 
studies, including the MM.1S cell line, which expresses ACA11 at 
very low levels. Forced expression of ACA11 in MM.1S cells reduced 
ROS levels, increased proliferation, and significantly protected the 
cells from cytotoxic chemotherapy (Figure 8, B–E). Knockdown 
of ACA11 significantly affected the proliferation, BrdU incorpo-
ration, and ROS levels in both t(4;14)-positive H929 and t(4;14)-
negative RPMI8226 cells, and these biologic effects were consis-
tently matched with the degree of knockdown achieved (Figure 8, 
F–K, and Supplemental Figure 7). Real-time PCR assays for ACA11 
expression found that in fact RPMI8226 cells expressed ACA11 at 
readily detectable levels, and ASO knockdown significantly reduced 
ACA11 levels in these cells. The consistent functional effects we 
observed using both ACA11 overexpression and well-controlled 
ASO knockdowns make the possibility of off-target ASO effects 
unlikely. Mateescu et al. (32) recently demonstrated that miR-200 
family members miR-141 and miR-200a increase ROS and sensitiv-
ity to chemotherapy via p38a in ovarian cancer. ACA11 provides 
essentially the opposite effect, i.e., suppression of ROS and protec-
tion of cells from chemotherapy (Figure 8, B, E, H, and K).
We believe that ACA11 is a novel element of t(4;14) biology. Does 
ACA11 by itself cause MM? We doubt that ACA11 overexpression 
alone will be sufficient to induce disease. The t(4;14) is found in 
patients with premalignant monoclonal gammopathy of undeter-
mined significance at rates comparable to those seen in patients 
with MM, suggesting that the t(4;14) itself is likely an early event 
in MM pathogenesis that alone is insufficient to cause MM. Fur-
Figure 5
RNA targets of the ACA11 ribonucleoprotein complex identified by RNP immunoprecipitation and deep sequencing. (A–F) Graphical representa-
tion of sequencing peaks mapping to the 6 targets of ACA11 snRNP. The horizontal gray bars indicate the locations of snoRNAs visualized in the 
UCSC genome browser. Arrows represent primers used for RT-PCR in H. (G) The same data as in E shown with lower vertical scale demonstrate 
smaller peaks of RPL10 exons. (H) RT-PCR confirms the presence of the indicated snoRNA intermediates resident within RP genes in the ILF3-, 
SF3B1-, or control IgG-precipitated complexes from H929 cells. H2O was used as a water template. GAPDH was used as control.
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Figure 6
A t(4;14) gene expression signature defined by mRNA expression microarray data from 239 samples from patients with myeloma. WHSC1 is 
upregulated in all 4p16 patients (arrow), and the nearby FGFR3 gene (arrow) is upregulated in most but not all 4p16 patients. Previously defined 
patient subgroup clusters (see Methods) are indicated by orange, dark green, red, dark blue, light green, and light blue. Highly significant down-
regulation (**P = 4.8 × 10–20) of RP genes was found in the 4p16 (i.e., WHSC1, orange) subgroup.
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Methods
Patient samples. RNAs from CD138-positive bone marrow cells of patients with 
MM were used for analysis. The t(4;14)-positive samples were assessed by FISH 
assay on whole bone marrow or CD138-enriched cells. Seven bladder, eight 
colon, and eight esophagus cancer and normal tissue control RNA samples 
were obtained anonymously from the Tissue Procurement Core Facility and 
Tumor Bank of Washington University in St. Louis, St. Louis, Missouri, USA.
Gene expression analysis. We analyzed the Multiple Myeloma Research Con-
sortium data set (GSE26760) of gene expression profiles of 239 patients with 
Affymetrix U133Plus2 platform, including 53 cases of 11q13, 25 cases of 4p16, 
4 cases of 6p21, 77 cases of cyclin D1, 39 cases of cyclin D2, 13 cases of D1+D2, 
thermore, 85% percent of t(4;14)-positive MM cases also harbor 
chromosome deletions that affect an unidentified tumor suppres-
sor gene on chromosome 13, suggesting that additional mutations 
are required for disease development. Conclusive demonstration 
of the role of ACA11 in MM pathogenesis will likely require the 
development of mouse models with complex genetics. An intrigu-
ing possibility is that WHSC1 proteins and the ACA11 snoRNA 
cooperate in MM pathogenesis. Taken together, our findings dem-
onstrate that ACA11 is a functionally important component of the 
t(4;14) translocation. Detection and/or pharmaceutical targeting 
of ACA11 may be useful in cancer patient care.
Figure 7
ACA11 provides evidence for the t(4;14) gene signature in part — ACA11 is sufficient to downregulate RP genes. (A) Overexpression of ACA11 
confirmed by Northern blot analysis in Arf–/– MEFs stably transduced with ACA11 lentiviruses. β-Actin was used as loading control. (B) Overex-
pression of ACA11 in Arf–/– MEFs as measured by qRT-PCR. (C) RP mRNA expression in Arf–/– MEFs overexpressing ACA11 was analyzed by 
qRT-PCR. (D) Expression of RPs in Arf–/– MEFs overexpressing ACA11 demonstrated by Western blot. γ-Tubulin was used as loading control. (E) 
Overexpression of ACA11 confirmed by Northern blot analysis in MM.1S cells stably transduced with ACA11 lentiviruses. β-Actin was used as 
loading control. (F) qRT-PCR showing the expression of ACA11 in MM.1S cells in E. (G) RP mRNA expression in MM.1S cells overexpressing 
ACA11 was analyzed by qRT-PCR. (H) Downregulation of RPs in MM.1S cells overexpressing ACA11 demonstrated by Western blot. γ-Tubulin was 
used as loading control. (I) Small RNAs were isolated from MM.1S cells overexpressing ACA11. snoRNA expression was analyzed by qRT-PCR. 
U43, snoRNA located in RPL3; U64, snoRNA located in RPS2; U32A, U33, and U35A, snoRNAs located in RPL13A. qRT-PCR data were normal-
ized to the average of 3 reference genes, (B, C, F, and G) GAPDH, UBC, and YWHAZ or (I) U6, U44, and U48, and are shown as fold change 
relative to that of mock-treated cells. Data represent mean ± SD (n = 3). *P < 0.05, **P < 0.01.
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RT-PCR and qRT-PCR. Total RNAs were extracted using TRIzol (Invitrogen) 
reagent, and small RNAs were isolated using a mirVana miRNA Isolation Kit 
(Ambion) and treated with RNase-free DNase I (Invitrogen) according to the 
manufacturer’s protocol. RT-PCR was performed according to the protocol 
of the SuperScript One-Step RT-PCR with Platinum Taq Kit (Invitrogen). 
qRT-PCR was performed using the iScript One-Step RT-PCR Kit with SYBR 
Green (Bio-Rad) or custom TaqMan small RNA assays (Applied Biosystems) 
for quantification of snoRNAs on the Miniopticon system (Bio-Rad) follow-
ing the manufacturer’s protocol. GAPDH, UBC, YWHAZ, U6, U44, and U48 
were used as reference genes. Quantitative data were analyzed using Qbaseplus 
software (Biogazelle). Each assay was performed in triplicate. Primer 
sequences are provided in Supplemental Table 6.
Northern blot. Total RNA was denatured, fractionated by electrophore-
sis, transferred to a nylon membrane (Amersham), and fixed by UV cross-
linking. The RNA blots were hybridized to 32P-labeled probes specific for 
ACA11 as previously described (34) or the biotin-labeled probes using the 
BrightStar BioDetect Kit (Ambion) according to the manufacturer’s pro-
tocol. The antisense biotin-labeled RNA probe was synthesized by in vitro 
transcription with T7 RNA polymerase (MAXIscript Kit, Ambion).
FISH and immunofluorescence. FISH assay was performed according to the 
protocol of R. Singer (http://singerlab.org/protocols). Fluorescein-labeled 
(Roche) or cyanine-labeled (PerkinElmer) RNA probes were used. p80-coil-
in was detected with monoclonal mouse anti-coilin and rhodamine-conju-
gated anti-mouse antibody (Abcam). Cell nuclei were visualized with DAPI. 
Images were acquired on a confocal microscope (Olympus, FV1000).
RNA EMSA and RNA affinity chromatography. We performed RNA EMSA 
and RNA affinity chromatography as described in the Supplemental Meth-
ods. Briefly, the 3′ end biotinylated sense RNA was incubated with native 
nuclear protein extracts and the EMSA binding buffer. The RNA-protein 
complexes were subjected to a nondenaturing polyacrylamide gel for EMSA 
analysis or purified using the high-capacity streptavidin agarose resin 
(Pierce), followed by resolving on a SDS-PAGE gel for further MS analysis.
MS. Electrospray-linear ion trap and Fourier transform ion cyclotron 
MS (LTQ FT, Thermo-Finnigan) was performed as described previously 
(35). Database searching was performed using a UniProt database select-
ed for Homo sapiens (downloaded on 12/6/2010, 97,048 entries). Scaffold 
(Proteome Software Inc.) was used to validate MS/MS-based peptide and 
protein identifications. Peptide and protein identifications were accepted 
if they could be established at greater than 95.0% probability as specified 
by the Peptide Prophet algorithm (36, 37). Molecular network analysis was 
performed using the IPA software (Ingenuity Systems).
Immunoprecipitation and Western blot. Immunoprecipitation and Western 
blot were performed as described previously (38). Antibodies are described 
in the Supplemental Methods.
Cross-linking ribonucleoprotein immunoprecipitation and RNA sequencing. CLIP 
was performed as described previously (39). The isolated RNA fragments 
were ligated to Illumina adaptors, followed by RT and PCR amplification. 
The prepared libraries were sequenced on the Illumina HiSeq 2000 platform. 
The model-based analysis for ChIP-Seq (MACS) algorithm was used for anal-
ysis. Detailed procedures are described in the Supplemental Methods.
ROS detection. 2′ ,7′-dichlorof luorescein diacetate (DCFH-DA, 
Sigma-Aldrich) was used to measure ROS generation. Fluorescence inten-
sity was quantified using a microplate fluorometer (BioTek) or flow cytom-
etry (BD) as described previously (28).
snoRNA knockdown. Chemically modified ASOs were used for knock-
down experiments, as described in the Supplemental Methods. ASOs tar-
geting GFP served as a control.
Cell growth, cell volume, cell mass, and proliferation assays. Cell growth curves 
were performed during 6 days of culture. Cell mass was measured by Brad-
ford assay (Bio-Rad), and cell volume was measured as described previously 
15 cases of MAF, and 13 cases defined as “None” (which refers to cases that 
did not fall into the 7 defined expression groups). The raw data were prepro-
cessed by robust multichip average normalization, and the analysis was con-
ducted using Bioconductor 2.8 under R 2.11. Using significance analysis of 
microarrays, we performed a one-to-one comparison between 4p16 (WHSC1) 
and the other 5 major subtypes (D1, D1+D2, D2, 11q13, and MAF [6p21 
and None were excluded due to the small sample sizes]), with a cutoff false 
discovery rate q value of less than 0.1. The resulting 5 lists (see Supplemental 
Table 4) were further intersected to find the genes consistently upregulated 
(or downregulated) specifically to WHSC1 subtype. Hypergeometric tests were 
performed using the Kyoto Encyclopedia of Genes and Genomes database. 
The data set was updated to 304 samples on May 23, 2011.
Tiling array design and hybridization. Custom arrays with 12 identical sections 
were manufactured by NimbleGen. Each section contained 60-bp probes span-
ning the entire region of chromosome 4, from 1.642 Mb to 2.072 Mb, includ-
ing both forward and reverse strands. Ten housekeeping genes covered by ten 
probes each served as controls. Every experimental and housekeeping probe 
was used in quadruplicate as an additional control. Five μg of total cellular 
RNAs were polyadenylated using Plus Module 10 Assay (Genisphere) accord-
ing to the manufacturer’s protocol. Double-stranded cDNA was created using 
the SuperScript Double-Stranded cDNA Synthesis Kit (Invitrogen). cDNA was 
then labeled with a DNA Labeling Kit (NimbleGen) and subsequently hybrid-
ized to a NimbleGen array using the NimbleGen Hybridization System. Data 
were analyzed using Partek Genomics Suite software. The overall expression 
profile of the region of interest was generated from the median values of the 
raw expression values of the quadruplicate tiling probes. Tiling array data have 
been deposited into NCBI GEO (GSE36685; http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?token=lhmpnoycusyqytq&acc=GSE36685).
RNA secondary structure prediction. RNA secondary structure was pre-
dicted using the Vienna RNA package (version 2.0.0, Theoretical Bio-
chemistry Group), based on the minimum free energy algorithm of 
Zuker and Stiegler (33).
Plasmid constructs and virus production. The coding region of ACA11 was 
amplified from human genomic DNA and subcloned to pBluescript II KS 
(+) vector (Stratagene) (pBS-ACA11) or lentiviral vector FCY-si. Lentivirus 
(FCY-ACA11-YFP) was generated by recombination as described in the 
Supplemental Methods.
Figure 8
ACA11 functions to modulate oxidative stress, cell proliferation, and resis-
tance to chemotherapy. (A and B) ROS levels, quantified by DCFH-DA 
(DCF) labeling, are suppressed by ACA11 expression in (A) Arf–/– MEFs 
or (B) MM.1S cells at baseline and upon challenge with hydrogen per-
oxide (H2O2). (C and D) ACA11 expression increased growth and prolif-
eration of MM.1S cells as measured by (C) cell counting and (D) BrdU-
ELISA relative to mock-treated cells. (E) ACA11 increased resistance of 
MM.1S cells to cytotoxic chemotherapy as measured by MTT viability 
assay. (F and G) Northern blot and qRT-PCR analyses of ACA11 knock-
down in H929 cells 4 days after transfection with ASOs. β-Actin was used 
as loading control. U23, unrelated snoRNA. αA2 and αA3 are ASOs that 
target ACA11. (H–K) Knockdown of ACA11 in H929 cells (H) increased 
ROS levels, (I) decreased cell growth, (J) decreased cell proliferation, 
and (K) decreased resistance to cytotoxic chemotherapy. (L and N) 
Growth of (L) KMS-11 and (N) RPMI8226 cells in immunocompromised 
mice is reduced by ACA11 knockdown. (M and O) qRT-PCR showing 
the expression of ACA11 in (M) KMS-11 and (O) RPMI8226 xenograft 
tumors. Cells were nucleofected with 600 pmol ASOs per 106 cells and 
cultured for (I) 24 hours or (H, J–L, and N) 48 hours before further analy-
sis. qRT-PCR data in G, M, and O were normalized to the average of 3 
reference genes (GAPDH, UBC, YWHAZ) and are shown as fold change 
relative to that of mock-treated cells. All data shown represent mean ± SD 
(n = 3 [A–E and G–K], n = 5 [L–O]). *P < 0.05, **P < 0.01.
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(25). Cell proliferation was detected using the Cell Proliferation ELISA 
BrdU (colorimetric) Kit (Roche) according to the manufacturer’s instruc-
tions or the MTT assay (Sigma-Aldrich).
Chemotherapy resistance assays. Cells were incubated with different doses of 
doxorubicin (Sigma-Aldrich) at the indicated concentrations (see Figure 8, 
E and K) or 50 μg/ml 5-fluorouracil (Sigma-Aldrich). Cellular viability was 
assessed by MTT assay after 44 hours of incubation or trypan blue exclu-
sion assay. Experiments were repeated 3 times.
Statistics. Data are shown as mean ± SD unless noted otherwise. Two-
tailed unpaired Student’s t test and 1-way ANOVA with a Bonferroni post-
hoc test were carried out using Prism (GraphPad Software). P < 0.05 was 
considered significant.
Study approval. Studies with human samples were approved by the 
human research protection office at Washington University in St. Louis, 
and informed consent from the patients was obtained in accordance with 
the Declaration of Helsinki. Animal studies were approved by the Animal 
Study Committee at Washington University in St. Louis.
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